Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus QVAR 40.
ARNUITY ELLIPTA vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid